α-2-macroglobulin in saliva is associated with glycemic control in patients with type 2 diabetes mellitus - PubMed (original) (raw)

α-2-macroglobulin in saliva is associated with glycemic control in patients with type 2 diabetes mellitus

Juan Pablo Aitken et al. Dis Markers. 2015.

Abstract

Background: Subjects with type 2 diabetes mellitus (DM2) require an adequate glycemic control to avoid diabetic complications. Currently, saliva biomarkers are used as a diagnostic tool and can be indicative of the degree of progression and control of various diseases. Several studies indicate that α-2-macroglobulin levels are elevated in diabetic patients.

Methods: 120 subjects with DM2 were enrolled and classified into two groups according to their glycemic control (percentage of glycated hemoglobin-A1c (HbA1c), <7% adequate glycemic control group; >7% inadequate glycemic control group). The relationship between α-2-macroglobulin levels from saliva samples and HbA1c was subsequently evaluated.

Results: We found a positive correlation between α-2-macroglobulin and HbA1c (r = 0.778 and P < 0.0001). Area under the receivers operating characteristic (ROC) curve of α-2-macroglobulin indicated a positive discrimination threshold of α-2-macroglobulin (AUC = 0.903, CI 95%: 0.847-0.959, P < 0.0001) to diagnose glycemic control.

Conclusions: Our data strongly suggest that the level of saliva α-2-macroglobulin is an indicator for the degree of glycemic control in diabetic patients and represents a promising alternative method to evaluate this parameter.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Box-plot showing the comparison of saliva levels of A2MG between patients with adequate and inadequate glycemic control (HbA1c percentages <7% and >7%).

Figure 2

Figure 2

Scatter diagram showing the association between HbA1 percentage and saliva levels of A2MG based on Pearson's correlation analysis.

Figure 3

Figure 3

ROC curve of saliva levels of A2MG in DM2 patients with inadequate glycemic control. Receiver operating characteristic (ROC) curves displayed a positive discrimination threshold of A2MG in saliva to diagnose inadequate glycemic control in subjects with DM2.

References

    1. Hu F. B. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care. 2011;34(6):1249–1257. doi: 10.2337/dc11-0442. - DOI - PMC - PubMed
    1. Holmer H. K., Ogden L. A., Burda B. U., Norris S. L. Quality of clinical practice guidelines for glycemic control in type 2 diabetes mellitus. PLoS ONE. 2013;8(4) doi: 10.1371/journal.pone.0058625.e58625 - DOI - PMC - PubMed
    1. Rohlfing C. L., Wiedmeyer H.-M., Little R. R., England J. D., Tennill A., Goldstein D. E. Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care. 2002;25(2):275–278. doi: 10.2337/diacare.25.2.275. - DOI - PubMed
    1. Strauss S. M., Tuthill J., Singh G., et al. A novel intraoral diabetes screening approach in periodontal patients: results of a pilot study. Journal of Periodontology. 2012;83(6):699–706. doi: 10.1902/jop.2011.110386. - DOI - PMC - PubMed
    1. Strauss S. M., Rosedale M., Pesce M. A., et al. Point-of-care HbA1c testing with the A1cNow test kit in general practice dental clinics: a pilot study involving its accuracy and practical issues in its use. Point of Care. 2014;13(4):142–147. doi: 10.1097/poc.0000000000000039. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources